Akari Therapeutics to Host Webinar on HSCT-TMA and the Potential of Nomacopan
Akari Therapeutics, Plc, a leading biotechnology company specializing in advanced therapies for autoimmune and inflammatory diseases, has announced its plans to host a virtual key opinion leader event on October 19, 2023, at 11:30 am ET. The primary focus of this event will be to discuss the patient care landscape for hematopoietic stem cell transplant-related […]
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
NEW YORK and LONDON, July 07, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that a patient has completed the course of investigational nomacopan treatment in the open-label, multi-center Phase III Part A clinical trial in pediatric hematopoietic stem cell transplant-related […]